Related Experiment Video
Updated: Jun 26, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
The role of RIPK1 in chronic obstructive pulmonary disease
Aman Tiwari1, Avtar Singh Gautam1, Shivam Kumar Pandey1
1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-Raebareli), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Lucknow 226002, Uttar Pradesh, India.
Necroptosis, a form of cell death, drives inflammation in chronic obstructive pulmonary disease (COPD). Targeting RIPK1-mediated necroptosis may offer new therapeutic strategies for COPD patients.
Area of Science:
- Pulmonary Medicine
- Cellular Biology
- Immunology
Background:
- Necroptosis is a key pathological process in chronic obstructive pulmonary disease (COPD).
- Airway epithelial necroptosis contributes to COPD pathogenesis by releasing inflammatory damage-associated molecular patterns (DAMPs).
- The precise mechanisms of necroptosis in COPD remain incompletely understood.
Purpose of the Study:
- To investigate the roles and mechanisms of receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-mediated necroptosis.
- To elucidate the regulation of inflammatory responses in COPD through RIPK1-mediated necroptosis.
- To provide insights for RIPK1-inhibitor drug discovery in COPD.
Main Methods:
- The study focuses on exploring the mechanisms of RIPK1-mediated necroptosis in COPD.
- Investigating the link between necroptosis and inflammatory responses in the context of COPD.
- Analyzing the potential of RIPK1 inhibitors for COPD therapeutics.
Main Results:
- Necroptosis, regulated by RIPK1, plays a significant role in COPD pathogenesis.
- Necroptotic airway epithelial cells release DAMPs, triggering inflammation.
- RIPK1-mediated necroptosis is a critical factor in COPD-associated inflammation.
Conclusions:
- RIPK1-mediated necroptosis is integral to the inflammatory processes in COPD.
- Understanding these mechanisms can guide the development of RIPK1-inhibitor therapies.
- Targeting RIPK1 may offer therapeutic benefits for managing COPD.
More Related Videos
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Regulation of the Unfolded Protein Response
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

